Valneva SE

Valneva reported H1 2026 product sales of €64.0 million and total revenues of €65.8 million, a decrease from H1 2025, primarily due to planned wind-down of third-party sales and expected phasing. The company reaffirmed its full-year guidance of €135-150 million for product sales. Valneva maintained a strong cash position of €121.5 million, reflecting disciplined management and proceeds from a recent offering, and implemented a restructuring program. Regulatory decisions for its Lyme disease vaccine candidate are expected within the next twelve months, with Pfizer expressing optimism.

Valneva SE announced it will report its first half 2026 consolidated financial results on Thursday, August 13, 2026. The specialty vaccine company will also host a live webcast at 3 p.m. CET / 9 a.m. ET to discuss these results and provide a business update. The webcast will be available on the company's website and archived for later access.

Valneva SE announced the successful outcome of its Annual General Meeting (AGM) held on June 25, 2026, where shareholders approved all recommended resolutions. Key approvals included the 2025 financial statements, renewal of share capital authorizations, and the transfer of the registered office to Lyon. Following the AGM, Dr. Gerd Zettlmeissl was appointed as the new Chair of the Board of Directors, succeeding Anne-Marie Graffin, who will now serve as Vice-chair.

Valneva SE has announced the details for its Annual General Meeting (AGM) scheduled for June 25, 2026. The official notice for the meeting was published on May 18, 2026. Shareholders can access all relevant information and preparatory documents online via the company's website, request them by email, or consult them at Valneva's registered office in Lyon.

Valneva announced that its partner Pfizer reported positive topline Phase 3 results for their Lyme disease vaccine candidate, demonstrating strong efficacy with no safety concerns. Pfizer is now planning submissions to regulatory authorities. Additionally, Valneva will engage with institutional investors at three conferences in June: Jefferies Global Healthcare Conference, Oddo BHF Nextcap Forum, and BNP Paribas SMID Cap Conference. The Company will also be a Gold Sponsor and Exhibitor at the 10th Northern European Conference on Travel Medicine.

Valneva SE reported a significant increase in net loss to €32.1 million in the first quarter of 2026, with total revenues declining to €30.9 million, primarily due to the wind-down of third-party sales and shipment phasing. The company revised its 2026 product sales guidance downwards to €135-150 million, citing adverse trends in travel vaccine uptake. Despite the financial downturn, Valneva reduced its operating cash burn to €0.3 million and launched a restructuring plan to cut operating expenses by 25-35% and workforce by 10-15%. Key pipeline progress includes Pfizer's expected regulatory submissions for the Lyme disease vaccine candidate and the authorization for local manufacturing of the Chikungunya vaccine in Brazil.

Valneva SE announced it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The specialty vaccine company will host a live webcast at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update. The webcast will be available on the company's website.

Valneva SE successfully completed an €84 million reserved offering, which includes €37 million expected upon closing and up to €47 million if all warrants are exercised. The closing is anticipated on May 5, 2026. The company intends to use the net proceeds to advance its vaccine pipeline, maximize growth of its commercial business, and for working capital and general corporate purposes, with an equal allocation between these two objectives. The offering was led by existing investor Frazier Life Sciences, with participation from new and existing investors.